Image Source: BING
Read more »

Labels: Aubagio, Study

By Kim Dolce—December 8, 2015

December is upon us, and besides being the holiday season, ‘tis also the season to renew our prescriptions for disease-modifying therapies and reapply for co-pay assistance.
Read more »

Labels: Aubagio, Avonex, Betaseron, Gilenya, Rebif

Read more »

Labels: Aubagio, Avonex, Betaseron, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

COPENHAGEN -- Teriflunomide (Aubagio) significantly reduced the risk of clinically definite multiple sclerosis in patients who had suffered a first bout of symptoms, an academic researcher confirmed here.
Read more »

Labels: Aubagio

#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion
Read more »

Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri

• "It takes about 2 x as long for someone with MS to absorb and process information as someone who does not have MS: Back to School With MS? Here's How"
• Multiple Sclerosis Treatment Options: Breakdown of Associated Risks
• Study: Tysabri (Natalizumab) to fingolimod washout in patients at risk of PMLFingolimod, Tysabri
• Neil Cavuto on Feeling Moved to Tell His Viewers: ‘It’s Not Me, It’s The Multiple Sclerosis’
• Merck KGaA shores up Rebif defenses to fend off new MS rivalsRebif
• Play the MS Matching Game: brain games can help exercise your mind
• Survey showed strong uptake of the new 40-milligram, thrice-weekly version of Teva's Copaxone, estimating that about 40% of MSers will have switched to it after two yearsCopaxone
• New warning suggested for Ambien...the same sleeping pill that landed a Kennedy before a jury: says patients shouldn't drive for 8 hours after they take meds like Ambien
• $15 Million awarded to former Newark teacher with MS who says district retaliated against her
• A Glittering Rock Reunion of 14,300 Fans Becomes the Best of Get-Well Gifts for Guitarist Ronnie Lane
• Study: 2014 Multiple Sclerosis Therapeutic Update, UCSF MS Department of Neurology, San Francisco, CA
• Study: High prevalence and no latitude gradient of multiple sclerosis in Norway
• Study: Supervised exercise training has substantial benefits for MSers, yet 80% of those with MS do not meet recommended levels of moderate-to-vigorous physical activity (MVPA)
• "British Health Minister Edwin Poots witnessed first-hand how oxygen therapy can help MSers enjoy a better quality of life"
• Illinois lottery game fund multiple sclerosis research
• BREAKING NEWS! WARNING: Pfizer Issues Nationwide Recall of Antidepressant Effexor
• For Runner With M.S., No Pain While Racing, No Feeling at the Finish (New York Times)
• A MSer's story of how she & her Neuro both had problems with Anthem BlueCross getting her MS treatment refilled:10 BEST
• Doctors’ #1 Source for Healthcare Information: Wikipedia
• Merck KGaA shores up Rebif defenses to fend off new MS rivals
• Novartis, Sanofi, Biogen tout new MS drug researchAubagio, Copaxone, Gilenya, Tysabri
• My recent struggles made me realize, you only live life one time
• "Innate Immunotherapeutics delivered results from animal studies which further support its novel MIS416 therapy as a candidate to treat Secondary Progressive Multiple "Sclerosis (SPMS)
• Oregon Health & Science University today announced the creation of the OHSU Center for Embryonic Cell and Gene Therapy, led by Shoukhrat Mitalipov, Ph.D., a world-renowned leader in embryonic stem cell and gene therapy research
• Study: Neglecting data from individuals with MS who exhibit head movement during functional magnetic resonance imaging (fMRI) scanning may bias sampling away from individuals with lower cognitive ability
• Study: MiR-126: a novel route for Tysabri (natalizumab) action?Tysabri
• "Dr. Monson has developed a validated method for pre-testing people living with MS to determine if they are a carrier of a unique antibody gene that leads to the disease, thus mitigating the long-standing challenge of diagnosis"
• MS trial to explore vitamin D links
• Study: Oxygen Cost of Walking in Persons with Multiple Sclerosis: Disability Matters, but Why?
• A SAD BUT IMPORTANT LESSON FOR ALL MSers: "Inquest hears how MSer dropped match or cigarette onto her bed that engulfed her in flames and burnt down her home
• This MSer believes marijuana helped put his MS in remission: soon however, Davidson will be forced to destroy the medicine he credits with saving his life
• Biogen Idec finished 2013 on a high note, with its highly touted oral multiple sclerosis drug Tecfidera producing nearly $400 million in sales during the fourth
• Study Findings from Biogen Idec, Inc. Provide New Insights into Multiple Sclerosis
• Slightest change makes myelin come unglued: One common characteristic of diseased myelin is swelling due to MS
• OMG of the week: Doctors flee homes after declaring strike
• What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?
• How Inactivity Change MSer's Brains
• One-liners may hint at feelings about health care
• RUNNING HELPS ME MANAGE MY MS: Jeanine Parson
• I'm a mother of 3 young children and here's my horror story of my MS & the new health care law
• TAKEDA ADMITS TO IMPROPERLY MARKETING BLOCKBUSTER DRUG a AFTER DOCTOR POINTS OUT DATA IN AD DIDNT MATCH RESULTS OF CLINICAL STUDY
• Study: “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis
• Clues To Causes Of Nerve Cell Degeneration in MS Provided By Spasticity Gene Finding
• Minn. physicians ponder medical pot: Is marijuana an effective treatment for pain, illness and disease?
• Study: MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge
• Variables associated with patient activation in persons with multiple sclerosis
• What Vitamin D Dosage Do I need? How Much Sun Do I Need?
• Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
• Express Scripts stops covering older, commonly used treatments such as Bayer's multiple sclerosis drug Betaseron on clinical, cost-effectiveness grounds
• Study: Antiviral drug Ganciclovir Inhibits Neuroinflammation in Mouse Model of MS
• Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis
• Study: Constraint-induced movement therapy increased neuroplasticity in MS patients according to MRI findings, whereas massage, yoga, and other "complementary/alternative medicine" treatments did not.
• Arshiya’s special talent: I used to jump all the way down the steps in Hodge Lee in one leap. I felt like Superman, or rather, Superwoman. That was before I got MS
• TEVA'S COPAXONE PATENT IS UP AND ITS DESPERATE TO KEEP PATIENTS & INSURERS
• DOES THIS NEW STUDY MEAN ANYTHING FOR MS PATIENTS?: "Medical Marijuana: Studies Find No Benefit for RA: Rheumatologists should not currently be recommending the use of medical marijuana to their patients for relief of chronic pain, researchers stated
• 4 Things All Doctors Need To Know About Health IT Security
• Video: THE SCANDAL THAT ROCKED THE PATIENT SAFETY MOVEMENT BREAK...
• CAN CAFFEINE HELP AN MSers MEMORY: Caffeine’s little memory jolt garners a lot of excitement
• Air Force Academy's future rests in Lt. Gen. Michelle Johnson steady hands: the institution's first female superintendent, has been tearing down barriers all her life including MS
• Senate Passes Casey MS Resolution Ahead of Multiple Sclerosis Awareness Week
• "MS doesn't define us - it's just there"
• 7 women are suing Doctor & health network for medical negligence, claiming the doctor misdiagnosed them with multiple sclerosis
• "My 1st experience as an immunologist diagnosed with MS" by Griselda Zuccarino-Catina, PH.D.
• DOCTORS BEDSIDE MANNER: written by a doctor
• Immunophenotyping Separates MS Subtypes by Neuroinflammation
• What's new in the fight against MS? USA Today
• Another big beast joins the MS Drug fray: ofatumumab phase 2 trial results
• MSnewsChanel.com.com
• Study may provide future insights into causes and mechanisms of MS
• 30% of the 16,651 people who died of an opioid overdose also had taken a benzodiazepine
• Working as a full time police officer & living with MS
• Here's 5 ways to help ease the pain of winter months
• Obamacare Hikes Cost to Patients of Specialty Drugs for MS
• The battle of a 6th grader recently diagnosed with MS
• Study: Stethoscopes carry more bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), than a physician’s hand
• Merck's Rebif is a 3rd major MS drug to be discovered in Israel: The Israeli Connection
• Kristen discovers running as way to combat her MS
• Cara Therapeutics has exciting new MS drugs in their pipeline
• Study: See One, Do One: Watching Action Boosts Brain Volume, Ability
• Study: Graph theoretical analysis indicates cognitive impairment in MS stems from neural disconnection
• We've posted 314 Studies & Stories for you so far this week
• FOR DOCTORS ONLY: 15 Smartphone Apps to Improve Your PracticeDocs Only
• WEEKEND LOL REPORT: Medical School Limiting the Number of Creepy Applicants to Cut Down on Creepy Doctors
• Video: 'Dallas Buyers Club' connects with MSers
• FOR DOCTORS ONLY: Study Companion: Mastering Clinical Concepts in MS Management

Labels: Aubagio, Betaseron, Gilenya, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!:

www.MSnewsChannel.com


ECTRIMS: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
ECTRIMS Congress 2013: SLIDE SHOW: WHY GREY MATTERS...BRAIN ATROPHY IN MS: WHAT ARE ITS CONSEQUENCES?

ECTRIMS Congress 2013: Higher Vitamin D Levels Linked to Less MS Activity
ECTRIMS Congress 2013: African Americans With MS at More Visual Risk

ECTRIMS Congress 2013: Biogen covers all bases for personalised approach to MS

Halting MS to Be Focus at ECTRIMS Congress 2013

ECTRIMS Congress 2013:  New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis

ECTRIMS Congress 2013: Scientists from ENDECE Neural presented preclinical data today showing that the company’s lead compound, NDC-1308, addresses one of the root causes of multiple sclerosis (MS) by significantly inducing remyelination in nerves that have been damaged by MS

ECTRIMS Congress 2013: Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

ECTRIMS Congress 2013: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -

ECTRIMS Congress 2013: Biogen Idec's new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least 4 years with no new safety problems

ECTRIMS Congress 2013: COPAXONE (Glatiramer acetate)  20 mg daily associated with stable disease activity over the course of the twenty-year study presented at the 29th ECTRIMS congress

ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates

ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE

ECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH
 
ECTRIMS Congress 2013: "BRAIN ATROPHY CAN PRECEDE MS SYMPTOM"

ECTRIMS Congress 2013: "EARLY, STEADY MS TREATMENT CUTS PROGRESSION RISK" (Day 1 ECTRIMS News)

ECTRIMS Congress 2013: Vitamin D for All to Prevent MS? Vitamin D for all MSers?

Labels: Aubagio, ECTRIMS CONGRESS 2013, Gilenya, TECFIDERA, Tysabri, Vitamin D

Read more »

Labels: 100 MOST POPULAR, Aubagio, Avonex, Gilenya, TECFIDERA

Read more »

Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Novantrone, Rebif, TECFIDERA, Tysabri

Read more »

Labels: Aubagio, Avonex, Betaseron, Gilenya, TECFIDERA, Tysabri

Read more »

Labels: Aubagio, Avonex, Gilenya, TECFIDERA

New data is rolling out at the European Committee for Treatment and Research in Multiple Sclerosis annual meeting this week, with the new slate of oral treatments in the spotlight, along with a lineup of older injectables and experimental drugs. So far, one common theme is this: Early treatment equals better results.
Read more »

Labels: Aubagio, Gilenya, Tysabri

Read more »

Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

Oral MS drugs could exacerbate Copaxone's decline. Meanwhile, the three main oral MS drugs -- Novartis' Gilenya, Biogen's Tecfidera, and Sanofi's Aubagio -- could all bury Copaxone in its key U.S. market. Click to read how fast these treatments have been selling, despite their limited time on the market.

Labels: Aubagio, Gilenya, TECFIDERA

 PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!



In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov



Read more »

Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, sativex, TECFIDERA, Tysabri

 PLUS: 1575 new Studies we posted from 11/1 to Wednesday 2/12 Start at the Bottom!




In the NARCOMS cohort, functional health literacy is high. However, lower levels of health literacy are associated with adverse health behaviors and greater health care utilization.
Read Study at Pubmed.gov

In the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.
Read Study at Pubmed.gov

Read more »

Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, sativex, TECFIDERA, Tysabri

 PLUS: 1560 new Studies we posted from 11/1 to Tuesday 2/11 Start at the Bottom!



Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed. 
Read Study at Pubmed.gov

The best current evidence for the efficacy of glucocorticoid treatment in MS, by far, comes from the optic neuritis treatment trial, which used high-dose intravenous methylprednisolone for the first 3 days followed by an 11-day course of low-dose oral prednisone. 
Read Study at Pubmed.gov

It is hoped that, through an understanding of the earliest aspects of the MS disease process, critical insights will be gained about the genesis of MS. 
Read Study at Pubmed.gov

Major technical improvements in MRI hardware and pulse sequence design allow more specific and potentially more sensitive treatment metrics required for targeting outcomes most relevant to neuronal degeneration, remyelination and repair. 
Read Study at Pubmed.gov

This chapter reviews the current evidence, taken from both clinical and paraclinical sources, as it relates to establishing this prognosis and provides insight to where, in the future, we need to look. 
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, sativex, TECFIDERA, Tysabri

 PLUS: 1545 new Studies we posted from 11/1 to Monday 2/10 Start at the Bottom!



These findings support previous systematic reviews, however publication bias cannot be excluded. The methodological conduct of studies could be improved, particularly with regard to reporting and conduct of laboratory analyses.
Read Study at Pubmed.gov

Despite the long follow-up, the risk of MS appears lower in New South Wales children compared to previously reported cohorts. Radiological features are more predictive than clinical features in predicting MS. The McDonald 2010 criteria performed well although the dissemination in time criteria on baseline scans is difficult to apply to children with encephalopathy.
Read study at Pubmed.gov

Our findings suggest that higher CR in individuals with MS may mediate between cognitive performance and brain pathology. CR-related compensation may, however, fail with progression of damage. The time window of opportunity for therapeutic approaches aimed at intellectual enhancement most likely lies in the earliest disease stages.
Read Study at Pubmed.gov

Further evidence of vitamin D deficiency as a causal factor, its molecular targets in MS and its prospect as a therapeutic and preventative agent are questions that warrant further study.
Read Study at Pubmed.gov

Patients with ≥2 relapses annually have higher resource utilization and costs. The difference in cost was over twice as large in treatment-naïve patients versus treatment-experienced patients. HRA was also associated with an increased likelihood of starting DMT treatment (treatment-naïve patients), and switching or discontinuing DMT therapy (treatment-experienced patients).
Read Study at Pubmed.gov 

Read more »

Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Novantrone, Rebif, sativex, TECFIDERA, Tysabri

 PLUS: 1530 new Studies we posted from 11/1 to Sunday 2/9 Start at the Bottom!

Farming and exposure to livestock may be important factors in the development of FCD among women, with this finding further revealed after the confounding effect of parity or number of children is considered.
Read Study at Pubmed.gov

Results suggest that demyelinated lesions in MS mainly have a remote effect on the thalamus and that the measurement of CBF using ASL could be an objective marker for monitoring disease activity in MS.
Read Study at Pubmed.gov

Here, we summarize currently accepted therapeutic principles and the drugs in late stages of development, as well as spotlighting potential novel openings for future research.
Read Study at Pubmed.gov

Collaboration between neurologists and psychiatrists whilst caring for patients displaying neuropsychiatric manifestations of MS is crucial to enable more accurate diagnoses and try to improve treatment and overall prognosis. 
Read Study at Pubmed.gov

In summary, in this retrospective analysis, daclizumab therapy substantially decreased the rate of brain atrophy in relapsing-remitting MS in comparison to other disease-modifying therapies, predominantly interferon β.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Novantrone, Rebif, sativex, TECFIDERA, Tysabri

 PLUS: 1515 new Studies we posted from 11/1 to Saturday 2/8 Start at the Bottom!


In this paper we present a new unsupervised approach addressing this problem with dictionary learning and sparse coding methods. We show its general applicability to the problem of lesion segmentation by evaluating our approach on synthetic and clinical image data and comparing it to state-of-the-art methods.
Read Study at Pubmed.gov

In this paper we will review the substantial literature regarding experimental and clinical use of these stem cells and possible mechanisms in the treatment of MS. These results may pave the road for the utilization of stem cells for the treatment of MS.
Read Study at Pubmed.gov

Long walking tests and patient-reported MSWS-12 were more appropriate than short walking tests in detecting clinically meaningful improvement after physical rehabilitation, particularly the MSWS-12 for moderate to severely disabled pwMS.
Read Study at Pubmed.gov

The use of patient self-assessed outcome measures that appraise the quality of diagnosis communication is also important to allow health services to understand and meet the needs and preferences of PwMS.
Read Study at Pubmed.gov

Quantitative gait assessment reveals subtle gait disorders in patients with low disability of relapsing-remitting multiple sclerosis. The impact of different cognitive domains on gait induces specific gait disturbances that highlight the strong interaction between gait and cognition.
Read Study at Pubmed.gov

Read more »

Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Novantrone, Rebif, sativex, TECFIDERA, Tysabri